Why take the continuous route? Because it leads to better, faster bioprocessing.
Sponsored By
Why adopt continuous bioprocessing? Because it can lead to faster and more cost-effective biopharma manufacturing. In this supplement, Pall and their collaborators discuss the benefits of continuous bioprocessing and how Pall is innovating in this area.
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
November 13, 2026
1 min read
Fujifilm Cellular Dynamics’ Delara Motlagh discusses her path into cell and gene therapy, the challenges of scaling manufacturing, and the potential of iPSC technologies
November 11, 2026
2 min read
The deal adds viral vector, bioconjugation, payload-linker, and advanced drug-delivery capabilities to Lonza’s manufacturing network
November 9, 2026
5 min read
As biologics portfolios expand and average product volumes fall, Miriam Monge asks whether today’s major manufacturing investments offer the flexibility tomorrow’s market will require
November 2, 2026
2 min read
Review examines how PAT, model-based control, reinforcement learning, and digital twins could maintain product quality from perfusion culture through downstream purification